U.S. drug regulators will decide whether to approve booster doses of Pfizer’s COVID-19 vaccine for all Americans aged 16 or older without convening its expert vaccine advisory panel, the Food and Drug Administration (FDA) confirmed to The Epoch Times on Nov. 17. The FDA’s acting head and other top Biden administration officials said earlier in 2021 that vaccine booster doses should be given to everyone because of waning vaccine efficacy against the virus that causes COVID-19. But the advisory panel recommended vaccine boosters for only certain groups, arguing that the data didn’t support the widespread administration of second and third vaccine doses. However, that panel won’t get a chance to weigh in as regulators consider Pfizer’s Nov. 9 request. “The FDA does not plan to hold a meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Pfizer’s request to amend their emergency use authorization to include the …